Table 1. Clinicopathological features of LUAD patients with high and low DLX1 expression.
Bold numbers represent significant values.
| Characteristic | Low expression of DLX1 | High expression of DLX1 | p |
|---|---|---|---|
| n | 256 | 257 | |
| T stage, n (%) | 0.237 | ||
| T1 | 94 (18.4%) | 74 (14.5%) | |
| T2 | 132 (25.9%) | 144 (28.2%) | |
| T3 | 23 (4.5%) | 24 (4.7%) | |
| T4 | 7 (1.4%) | 12 (2.4%) | |
| N stage, n (%) | 0.050 | ||
| N0 | 169 (33.7%) | 161 (32.1%) | |
| N1 | 37 (7.4%) | 58 (11.6%) | |
| N2 | 43 (8.6%) | 31 (6.2%) | |
| N3 | 1 (0.2%) | 1 (0.2%) | |
| M stage, n (%) | 0.354 | ||
| M0 | 178 (48.2%) | 166 (45%) | |
| M1 | 10 (2.7%) | 15 (4.1%) | |
| Pathologic stage, n (%) | 0.019 | ||
| Stage I | 149 (29.5%) | 125 (24.8%) | |
| Stage II | 47 (9.3%) | 74 (14.7%) | |
| Stage III | 45 (8.9%) | 39 (7.7%) | |
| Stage IV | 10 (2%) | 16 (3.2%) | |
| OS event, n (%) | 0.030 | ||
| Alive | 175 (34.1%) | 151 (29.4%) | |
| Dead | 81 (15.8%) | 106 (20.7%) | |
| DSS event, n (%) | 0.007 | ||
| Alive | 196 (41.1%) | 166 (34.8%) | |
| Dead | 45 (9.4%) | 70 (14.7%) | |
| PFI event, n (%) | 0.034 | ||
| Alive | 164 (32%) | 140 (27.3%) | |
| Dead | 92 (17.9%) | 117 (22.8%) | |
| Gender, n (%) | 0.504 | ||
| Female | 142 (27.7%) | 134 (26.1%) | |
| Male | 114 (22.2%) | 123 (24%) | |
| Age, median (IQR) | 66 (59, 73) | 66 (59.5, 72) | 0.774 |